Tags » GlaxoSmithKline

Neuzugang GlaxoSmithKline

Unser neuester Zugang im Portfolio ist GlaxoSmithKline, ein weltweit führender Arzneimittelhersteller, Forschungskonzern und Anbieter von Gesundheitsprodukten. Das Portfolio von GlaxoSmithKline umfasst Produkte zur Prävention und der Behandlung von akuten und chronischen Erkrankungen. 155 more words

Einzelwerte

UNC and GlaxoSmithKline pledge to cure AIDS

Since 1981, when UNC Hospitals admitted its first patient with AIDS, UNC has worked toward the bold goal of curing a patient with HIV.

Now UNC hopes to accelerate the discovery of a cure for AIDS by partnering with GlaxoSmithKline, a world leader in AIDS research. 544 more words

The Daily Tar Heel Articles

Upcoming Ex-dividend dates for Top 100

Ex-dividend dates are important to dividend growth investors because one must own a stock before its ex-dividend date in order to be eligible to receive its next dividend. 57 more words

Dividends

Why We Invested So Heavily in Johnson & Johnson

When we sat down and thought about starting our investment portfolio we had a simple objective in mind: earn enough in dividend income throughout our working lives so that we can cover our expenses during retirement from our dividends. 780 more words

Explanation

Gene Therapy And Rare Diseases: In The News #1

This is the 1st in a series of Blog Posts on the topic of recent news developments in gene therapy and rare diseases.

The following gene therapies will be reviewed in this Blog Post: 529 more words

Orphan Drug Development

UNC, GSK create new company to cure HIV/AIDS

UNC announced a partnership with leading pharmaceutical company GlaxoSmithKline to research and develop a cure for AIDS at a press conference on Monday.

UNC and GSK will create a new company, Qura Therapeutics, and a new center, the HIV Cure Center. 477 more words

The Daily Tar Heel Articles